(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 August 2022 (04.08.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/165288 A1

(51) International Patent Classification:
A61K 31/192 (2006.01) *A61P 1/16* (2006.01)

(21) International Application Number:
PCT/US2022/014464

(22) International Filing Date:
29 January 2022 (29.01.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/144,355 01 February 2021 (01.02.2021) US

(71) Applicant: **CYMABAY THERAPEUTICS, INC.** [US/US]; 7575 Gateway Boulevard, Suite 110, Newark, CA 94560 (US).

(72) Inventors: **CHOI, Yun-Jung**; c/o CymaBay Therapeutics, Inc., 7575 Gateway Boulevard, Suite 110, Newark, CA 94560 (US). **MCWHERTER, Charles A.**; c/o CymaBay Therapeutics, Inc., 7575 Gateway Boulevard, Suite 110, Newark, CA 94560 (US). **STEINBERG, Alexandra S.**; c/o CymaBay Therapeutics, Inc., 7575 Gateway Boulevard, Suite 110, Newark, CA 94560 (US). **YANG, Ke**; c/o CymaBay Therapeutics, Inc., 7575 Gateway Boulevard, Suite 110, Newark, CA 94560 (US).

(74) Agent: **NGUYEN, Sam L.** et al.; HDC IP Law, LLP, 24781 Anchor Lantern, Dana Point, CA 92629 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: TREATMENT OF CHOLANGIOPATHIES WITH SELADELPAR

(57) Abstract: Seladelpar and its salts are useful in the treatment of cholangiopathies in subjects who are intolerant of, or have an inadequate response to, obeticholic acid and/or fibrates.

WO 2022/165288 A1